Pharmaron Beijing Co., Ltd. (HKG: 3759)

Pharmaron Beijing Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	11,790	11,533	10,240	7,419	5,114	3,737
Other Revenue	4.61	4.61	26.19	24.48	19.55	19.81
Revenue	11,795	11,538	10,266	7,444	5,134	3,757
Revenue Growth (YoY)	3.25%	12.39%	37.92%	45.00%	36.64%	29.20%
Cost of Revenue	7,771	7,422	6,502	4,768	3,215	2,424
Gross Profit	4,024	4,116	3,764	2,676	1,919	1,333
Selling, General & Admin	1,845	1,859	1,728	1,022	745.89	568.58
Research & Development	483.77	448.28	282.32	151.77	105.35	62.87
Other Operating Expenses	166.02	82.75	66.52	44.04	32.9	31.24
Operating Expenses	2,537	2,426	2,098	1,229	898.95	668.19
Operating Income	1,487	1,690	1,667	1,448	1,020	665.16
Interest Expense	-241.52	-182.19	-167.31	-83.07	-23.85	-82.48
Interest & Investment Income	690.3	78.95	109.74	371.99	231.55	9.61
Currency Exchange Gain (Loss)	147	147	-42.39	-3.16	-131.23	1.88
Other Non Operating Income (Expenses)	-4.57	-3.61	-2.54	-1.39	-1.35	-1.23
EBT Excluding Unusual Items	2,078	1,730	1,564	1,732	1,095	592.96
Gain (Loss) on Sale of Investments	-43.58	18.75	68.09	119.59	190.86	6.73
Gain (Loss) on Sale of Assets	-33.32	-9.15	-15.3	-4.25	-7.28	-0.67
Asset Writedown	1.25	-	-	-	-	-
Other Unusual Items	136.28	98.48	49.5	63.73	40.72	33.53
Pretax Income	2,139	1,838	1,666	1,911	1,319	632.55
Income Tax Expense	322.35	256.11	314.25	290.92	172.38	101.88
Earnings From Continuing Operations	1,816	1,582	1,352	1,620	1,147	530.67
Minority Interest in Earnings	67.39	19.32	22.47	40.95	25.39	16.52
Net Income	1,884	1,601	1,375	1,661	1,172	547.19
Net Income to Common	1,884	1,601	1,375	1,661	1,172	547.19
Net Income Growth	21.34%	16.48%	-17.24%	41.68%	114.25%	64.30%
Shares Outstanding (Basic)	1,772	1,772	1,774	1,781	1,779	1,486
Shares Outstanding (Diluted)	1,775	1,775	1,776	1,820	1,785	1,487
Shares Change (YoY)	0.06%	-0.05%	-2.40%	1.97%	20.06%	11.85%
EPS (Basic)	1.06	0.90	0.78	0.93	0.66	0.37
EPS (Diluted)	1.06	0.90	0.77	0.91	0.66	0.37
EPS Growth	21.27%	16.54%	-15.21%	38.94%	78.46%	46.89%
Free Cash Flow	370.77	-111.78	-807.04	-34.78	332.77	183.98
Free Cash Flow Per Share	0.21	-0.06	-0.45	-0.02	0.19	0.12
Dividend Per Share	0.200	0.200	0.200	0.200	0.133	0.067
Dividend Growth	0%	0%	0%	50.04%	99.85%	36.40%
Gross Margin	34.12%	35.67%	36.67%	35.95%	37.38%	35.49%
Operating Margin	12.61%	14.64%	16.23%	19.45%	19.87%	17.70%
Profit Margin	15.97%	13.88%	13.39%	22.31%	22.84%	14.56%
Free Cash Flow Margin	3.14%	-0.97%	-7.86%	-0.47%	6.48%	4.90%
EBITDA	2,345	2,420	2,227	1,852	1,325	928.02
EBITDA Margin	19.88%	20.97%	21.70%	24.88%	25.81%	24.70%
D&A For EBITDA	857.66	730.42	560.76	404.64	304.85	262.86
EBIT	1,487	1,690	1,667	1,448	1,020	665.16
EBIT Margin	12.61%	14.64%	16.23%	19.45%	19.87%	17.70%
Effective Tax Rate	15.07%	13.93%	18.86%	15.22%	13.07%	16.11%
Revenue as Reported	11,795	11,538	10,266	7,444	5,134	3,757

Source: S&P Capital IQ. Standard template. Financial Sources.